Morristown-based Alvogen Inc. announced two lots of a transdermal patch used for delivery of the synthetic opioid Fentanyl have been recalled because the patches inside some cartons may contain a ...

Credit: Alvogen, Inc. Fentanyl is an opioid agonist indicated for the management of severe or persistent pain in opioid-tolerant patients. At this time, Alvogen Inc has received 1 serious adverse ...

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company today announced the launch of its new Sancuso ® (granisetron transdermal system) website. The website is designed to ...

Objective: To summarize the pharmaceutics, pharmacokinetics, development, and clinical application of IONSYS, the fentanyl HCl patient-controlled iontophoretic transdermal system for the management of ...

Alvogen, Inc. is voluntarily recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches to the consumer level. The reason for the recall is that there is a potential that patches ...

Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function The transdermal GFR (tGFR) methodology has ...

VANCOUVER, BC / ACCESSWIRE / June 8, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, ...

The US Food and Drug Administration (FDA) has approved donepezil transdermal system (Adlarity) for patients with mild, moderate, or severe Alzheimer's disease (AD), the manufacturer has announced.

DUBLIN--(BUSINESS WIRE)--The "Transdermal Drug Delivery System Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering. The transdermal drug delivery system ...

Philadelphia, US – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that its methylphenidate transdermal system (MTS), DAYTRANA TM demonstrated statistically significant reductions in the ...

FREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the publication of Phase 1 clinical trial data ...